Low dose dopamine infusion reduces renal tubular injury following cardiopulmonary bypass surgery.
Journal of Nephrology
397 - 402.
BACKGROUND: The use of dopamine to protect the kidneys against hypoperfusion injury remains controversial with little clinical evidence of benefit and increasing concerns regarding safety. In this double-blind, prospective, randomised study, we investigated the effect of dopamine infusion (2.5 microg/kg/min) on glomerular filtration rate (GFR) and tubular injury in patients undergoing routine cardiopulmonary bypass (CPB). METHODS: Forty eight patients were randomly assigned to receive intravenous dopamine or saline from induction of anaesthesia until 48 hours post-operatively. There were no differences in mean age, bypass time or pre-op creatinine in the 36 patients (33 men) who completed the study. 51Cr-EDTA GFR (ml/min/1.73 m2) was measured pre- operatively and on day 5 only. Urinary markers of tubular injury (albumin, N-acetyl glucosaminidase, NAG; retinol binding protein, RBP) were measured pre-operatively, and on days 1, 2 and 5. RESULTS: GFR was preserved equally in both groups. All patients demonstrated significant tubular injury but urinary levels of NAG and RBP were lower in the dopamine group (41%, p=0.057 and 41%, p=0.007, respectively) on the first post-operative day. CONCLUSION: We conclude that low dose dopamine infusion may reduce renal tubular injury following CPB in patients with normal or near normal baseline renal function
|Title:||Low dose dopamine infusion reduces renal tubular injury following cardiopulmonary bypass surgery|
|Additional information:||UI - 21586738 LA - eng RN - 0 (Cardiotonic Agents) RN - 51-61-6 (Dopamine) PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial DA - 20011203 IS - 1120-3625 SB - IM CY - Italy|
|Keywords:||Bypass, Bypass Surgery, Cardiopulmonary Bypass, CAT11, dopamine, dose, INFUSION, injuries, injury, Low, Low dose, MED-NEPH, renal, surgery, administration & dosage, adverse effects, age, Aged, AGENT, AGENTS, Albumin, anaesthesia, benefit, BINDING, BINDING PROTEIN, BINDING-PROTEIN, Bypass, Cardiotonic Agents, clinical, Clinical trial, CLINICAL-TRIAL, CONTROLLED TRIAL, Coronary Arteriosclerosis, Creatinine, difference, DOUBLE BLIND, DOUBLE-BLIND, Double-Blind Method, drug effects, etiology, Female, Filtration, function, GFR, glomerular, glomerular filtration, Glomerular Filtration Rate, GLOMERULAR-FILTRATION-RATE, groups, Heart Valve Diseases, IM, INDUCTION, Infusions, Intravenous, INTRAVENOUS, Italy, Kidney, Kidney Failure, Acute, Kidney Tubules, kidneys, LA, LEVEL, M2, Male, MARKER, Markers, May, MEN, Methods, Middle Age, pathology, Patient, patients, prevention & control, Prospective Studies, PROTEIN, randomized, RANDOMIZED CONTROLLED TRIAL, REMAINS, Renal Circulation, RENAL FUNCTION, RENAL-FUNCTION, Result, retinol binding protein, Safety, Saline, Support, Non-U.S.Gov't, TIME, Treatment Outcome, TRIAL, URINARY, Use|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only